GlassScriptPhysician profile
Ryan W Winters
NPI 1598702185
$2,930.54
in general payments reported to CMS, 2019-2025
19 companies · $591 in 2025
The $591 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $151 · 2021: $248 · 2022: $401 · 2023: $560 · 2024: $666 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $587.25 | 2022-2025 | Infuse, Miebo, Infuse Multifocal |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $492.43 | 2019-2021 | |
| Alcon Vision LLC | $462.05 | 2020-2025 | Total30, Rocklatan, Rhopressa |
| Coopervision INC. | $271.59 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $200.43 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $136.21 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $125.00 | 2024 | Izervay |
| Abbvie INC. | $123.34 | 2022 | |
| Glaukos Corporation | $122.77 | 2025 | Photrexa Viscous and Photrexa |
| Novartis Pharmaceuticals Corporation | $87.78 | 2022-2023 | |
| Amgen INC. | $67.50 | 2024 | Tepezza |
| Lkc Technologies, INC. | $61.18 | 2025 | |
| Optos, INC. | $50.75 | 2019 | |
| Oyster Point Pharma, INC. | $41.51 | 2022-2023 | Tyrvaya |
| Lombart Brothers, INC. | $23.58 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $23.07 | 2024 | Oxervate |
| Quidel Corporation | $22.30 | 2020 | |
| Carl Zeiss Meditec, INC. | $18.47 | 2019 | |
| Kala Pharmaceuticals, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.